Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HCAT Stock Forecast 2026-2027
$1.52
Current Price
$112.31M
Market Cap
Buy 2
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to HCAT Price Targets
+31.6%
To High Target of $2.00
+31.6%
To Median Target of $2.00
-34.2%
To Low Target of $1.00
HCAT Price Momentum
-3.2%
1 Week Change
+52.0%
1 Month Change
-63.2%
1 Year Change
-36.4%
Year-to-Date Change
-70.0%
From 52W High of $5.06
+59.2%
From 52W Low of $0.95
📊 TOP ANALYST CALLS
Did HCAT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Health Catalyst is one of their latest high-conviction picks.
Latest HCAT Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, HCAT has a neutral consensus with a median price target of $2.00 (ranging from $1.00 to $2.00). The overall analyst rating is Buy (7.0/10). Currently trading at $1.52, the median forecast implies a 31.6% upside. This outlook is supported by 2 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Grossman at Stifel, projecting a 31.6% upside. Conversely, the most conservative target is provided by Stan Berenshteyn at Wells Fargo, suggesting a 34.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HCAT Analyst Ratings
2
Buy
6
Hold
0
Sell
HCAT Price Target Range
Low
$1.00
Average
$2.00
High
$2.00
Current: $1.52
Latest HCAT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HCAT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 18, 2026 | Wells Fargo | Stan Berenshteyn | Equal-Weight | Downgrade | $1.00 |
| Mar 13, 2026 | Stifel | David Grossman | Hold | Maintains | $2.00 |
| Mar 13, 2026 | Stephens & Co. | Jeff Garro | Equal-Weight | Maintains | $2.00 |
| Mar 13, 2026 | Citigroup | Daniel Grosslight | Neutral | Maintains | $1.75 |
| Mar 13, 2026 | Canaccord Genuity | Richard Close | Buy | Maintains | $2.00 |
| Mar 13, 2026 | Cantor Fitzgerald | Sarah James | Neutral | Maintains | $3.00 |
| Jan 9, 2026 | Citigroup | Daniel Grosslight | Neutral | Maintains | $2.75 |
| Nov 11, 2025 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $5.00 |
| Nov 11, 2025 | Citigroup | Daniel Grosslight | Neutral | Maintains | $3.25 |
| Nov 11, 2025 | Stifel | David Grossman | Hold | Maintains | $3.75 |
| Oct 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $4.00 |
| Oct 8, 2025 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $3.00 |
| Oct 7, 2025 | Cantor Fitzgerald | Sarah James | Neutral | Reiterates | $4.00 |
| Sep 5, 2025 | BTIG | David Larsen | Neutral | Reiterates | $N/A |
| Aug 29, 2025 | Canaccord Genuity | Richard Close | Buy | Maintains | $5.00 |
| Aug 28, 2025 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $4.00 |
| Aug 27, 2025 | Piper Sandler | Jessica Tassan | Neutral | Downgrade | $4.00 |
| Aug 11, 2025 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $6.00 |
| Aug 8, 2025 | Stifel | David Grossman | Hold | Maintains | $4.50 |
| Aug 8, 2025 | Citigroup | Daniel Grosslight | Neutral | Downgrade | $3.50 |
Health Catalyst Inc (HCAT) Competitors
The following stocks are similar to Health Catalyst based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HCAT
Health Catalyst
mkt cap
112.31M
Health Catalyst Inc (HCAT) Financial Data
Health Catalyst Inc has a market capitalization of $112.31M with a P/E ratio of -0.6x. The company generates $311.14M in trailing twelve-month revenue with a -57.2% profit margin.
Revenue growth is -6.2% quarter-over-quarter, while maintaining an operating margin of -4.3% and return on equity of -58.3%.
Valuation Metrics
Market Cap
$112.31M
Enterprise Value
$187.36M
P/E Ratio
-0.6x
PEG Ratio
0.0x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
-6.2%
Gross Margin
+52.7%
Operating Margin
-4.3%
Net Margin
-57.2%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+85.6%
Current Ratio
1.9x
Debt/Equity
69.7x
ROE
-58.3%
ROA
-4.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Health Catalyst Inc (HCAT) Business Model
About Health Catalyst Inc
What They Do
Provides data and analytics solutions for healthcare.
Business Model
The company generates revenue through two primary segments: Technology and Professional Services. It offers cloud-based subscriptions, licenses, and support for its analytics platforms, while also providing consulting and implementation services to help healthcare organizations optimize their data usage and improve operational efficiency.
Additional Information
Founded in 2008 and based in South Jordan, Utah, Health Catalyst emphasizes security and compliance, holding certifications for various products. Its Health Catalyst Ignite platform is designed to integrate diverse healthcare data, enabling clients to achieve significant improvements in clinical quality, cost management, and overall operational performance.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
1,500
CEO
Mr. Daniel D. Burton
Country
United States
IPO Year
2019
Website
www.healthcatalyst.comHealth Catalyst Inc (HCAT) Latest News & Analysis
Latest News
Quick Summary
Health Catalyst (HCAT) is expected to report its Q1 2026 performance with an emphasis on key metrics beyond typical Wall Street estimates for a deeper analysis.
Why It Matters
Evaluating Health Catalyst's performance beyond standard estimates can reveal insights into growth potential, operational efficiency, and market positioning, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Health Catalyst, Inc. (Nasdaq: HCAT) will report Q1 2026 results on May 11, 2026, after market close, followed by a conference call at 5:00 pm ET.
Why It Matters
Health Catalyst's upcoming Q1 2026 results and conference call may influence stock performance, offering insights into financial health and operational progress, impacting investor sentiment and decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Health Catalyst, Inc. (Nasdaq: HCAT) appointed Steve Nelson of Aetna to its Board, effective May 1, 2026. This follows recent leadership changes aimed at enhancing health system performance.
Why It Matters
Steve Nelson's appointment to Health Catalyst's Board signals strategic leadership changes aimed at enhancing the company's focus on improving healthcare systems, potentially impacting its growth and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Health Catalyst, Inc. (HCAT) held its Q4 2025 earnings call, discussing financial performance and future outlook. Details on revenue, expenses, and strategic initiatives were highlighted.
Why It Matters
Health Catalyst's Q4 2025 earnings call provides insights into financial performance, growth strategies, and market trends, impacting investor confidence and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Health Catalyst (Nasdaq: HCAT) reported 2025 revenue of $311.1 million and Adjusted EBITDA of $41.4 million, highlighting strong performance and a focus on long-term success in 2026.
Why It Matters
Health Catalyst's solid financial results indicate strong business performance and growth potential, which may enhance investor confidence and influence stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Health Catalyst (HCAT) reported Q3 earnings of $0.08 per share, below the Zacks Consensus Estimate of $0.09. This is an increase from $0.04 per share in the same quarter last year.
Why It Matters
Health Catalyst's earnings miss signals potential operational challenges, which could affect investor confidence and stock performance despite year-over-year growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About HCAT Stock
What is Health Catalyst Inc's (HCAT) stock forecast for 2026?
Based on our analysis of 20 Wall Street analysts, Health Catalyst Inc (HCAT) has a median price target of $2.00. The highest price target is $2.00 and the lowest is $1.00.
Is HCAT stock a good investment in 2026?
According to current analyst ratings, HCAT has 2 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HCAT stock?
Wall Street analysts predict HCAT stock could reach $2.00 in the next 12 months. This represents a 31.6% increase from the current price of $1.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Health Catalyst Inc's business model?
The company generates revenue through two primary segments: Technology and Professional Services. It offers cloud-based subscriptions, licenses, and support for its analytics platforms, while also providing consulting and implementation services to help healthcare organizations optimize their data usage and improve operational efficiency.
What is the highest forecasted price for HCAT Health Catalyst Inc?
The highest price target for HCAT is $2.00 from David Grossman at Stifel, which represents a 31.6% increase from the current price of $1.52.
What is the lowest forecasted price for HCAT Health Catalyst Inc?
The lowest price target for HCAT is $1.00 from Stan Berenshteyn at Wells Fargo, which represents a -34.2% decrease from the current price of $1.52.
What is the overall HCAT consensus from analysts for Health Catalyst Inc?
The overall analyst consensus for HCAT is neutral. Out of 20 Wall Street analysts, 2 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are HCAT stock price projections?
Stock price projections, including those for Health Catalyst Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 12:30 PM UTC